Document Detail

Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial.
MedLine Citation:
PMID:  11231436     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Although more than 9500 patients have been enrolled in major clinical trials in Latin America, practice patterns in this region have rarely been examined. We sought to compare characteristics, resource utilization, and outcomes of patients treated for acute coronary syndromes in Latin America with those in North America. METHODS: The Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Theraphy Trial (PURSUIT) enrolled 10,948 patients with non-ST-segment elevation acute coronary syndromes, including 585 in Latin America and 4358 in North America. We analyzed regional differences in patient groups, treatment patterns, and outcomes and used logistic regression analysis to identify association of enrollment region and survival. RESULTS: For patients in Latin America, the length of hospital stay was significantly longer (10 [7, 15] days vs 6 [4, 9], P <.001). Angiograms, angioplasty, and bypass surgery were significantly less common in Latin America (46.2%, 17.6%, and 11.3% vs 79.4%, 33.6%, and 19.4%, P <.001). Thirty-day death/myocardial infarction was not significantly higher, although mortality alone was significantly higher (6.8% vs 3.1%, P <.001). After adjustment for baseline characteristics, enrollment in Latin America remained an independent predictor for death at 30 days (odds ratio [OR] [95% confidence interval (CI)] 2.42 [1.60-3.67]) and persisted at 6 months (OR [95% CI] 2.5 [1.8-3.4]). CONCLUSIONS: Latin American patients treated for acute coronary syndromes were managed less invasively and were twice as likely as their North American counterparts to die within 6 months. This mortality difference was not explained by imbalances in baseline risk.
M G Cohen; C M Pacchiana; R Corbalán; J E Perez; C I Ponte; E S Oropeza; R Diaz; E Paolasso; D Izasa; M A Rodas; C E Urrutia; R A Harrington; E J Topol; R M Califf
Related Documents :
20362246 - Health-related quality of life: a comparison of outcomes after lumbar fusion for degene...
22729666 - Acetabular rim lesions: arthroscopic assessment and clinical relevance.
8556396 - Long-term follow-up of symptomatic hiv-infected patients originally randomized to early...
22330176 - The course of limitations in activities over 5 years in patients with knee and hip ost...
22127896 - Autologous haematopoietic stem cell transplantation with an intermediate intensity cond...
21531576 - Intravenous tissue plasminogen activator for patients with minor ischemic stroke.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American heart journal     Volume:  141     ISSN:  0002-8703     ISO Abbreviation:  Am. Heart J.     Publication Date:  2001 Mar 
Date Detail:
Created Date:  2001-03-20     Completed Date:  2001-04-19     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  391-401     Citation Subset:  AIM; IM    
Duke Clinical Research Institute, Durham, NC, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angina, Unstable / drug therapy*,  mortality*
Latin America / epidemiology
Length of Stay
Logistic Models
Middle Aged
North America / epidemiology
Peptides / therapeutic use*
Physician's Practice Patterns*
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
Randomized Controlled Trials as Topic
Reg. No./Substance:
0/Peptides; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/eptifibatide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Gated single-photon emission computed tomographic myocardial imaging: a new tool in clinical cardiol...
Next Document:  Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use du...